Clinical trials: Solid Cancers
Advanced Solid Tumors
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
This is a study in patients with advanced solid tumors for the investigation of P-gp inhibition and induction on the PK of talazoparib.
- Trial name
- NCT03077607
- Testing
- Talazoparib, Itraconazole, Rifampin
- Where
- 7 sites in Hungary, Moldova and 2 more
- Volunteers
- 36 people
- Sponsor
- Pfizer
Advanced Solid Neoplasms
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of…
- Trial name
- NCT03742895
- Testing
- Olaparib
- Where
- 130 sites in United States, Argentina and 19 more
- Volunteers
- 329 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer, Solid Tumor
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
This is a Phase II, two part trial (A and B), open label study of Atezolizumab and tiragolumab, or atezolizumab combined with SOC chemotherapy in patients with NSCLC or advanced solid tumors that have had prior treatment with a…
- Trial name
- NCT03977467
- Testing
- Atezolizumab, Standard of Care Chemotherapy, Tiragolumab
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- SCRI Development Innovations, LLC
Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT01154816
- Testing
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 105 sites in United States, Canada
- Volunteers
- 118 people
- Sponsor
- Children's Oncology Group
Solid Tumor
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
Baseline levels of PAR-4 secreted by normal cells are generally inadequate to cause massive apoptosis in cancer cells and drugs that bolster the secretion of PAR-4 would constitute an important therapeutic advance.The apoptosis…
- Trial name
- NCT02232243
- Testing
- Hydroxychloroquine, 200mg twice dailiy, Hydroxychloroquine, 400mg twice daily
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Peng Wang, MD PhD
Solid Tumor, Non-Small Cell Lung Cancer Recurrent
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer Recurrent, Hepatocellular Carcinoma Recurrent
- Trial name
- NCT02423343
- Testing
- Galunisertib, Nivolumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic Solid Tumor
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic…
- Trial name
- NCT03717415
- Testing
- Rebastinib, Carboplatin
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Solid Tumors
AZD1775 for Advanced Solid Tumors
BACKGROUND: Wee1 is a tyrosine kinase involved in the phosphorylation and inactivation of cyclin-dependent kinase 1 (CDK1/CDC2)-bound cyclin B, resulting in G2 cell cycle arrest in response to deoxyribonucleic acid (DNA) damage…
- Trial name
- NCT01748825
- Testing
- MK-1775 (AZD1775)
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced, Metastatic Solid Tumors
A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
The purpose of this study is to compare the safety and tolerability of several dose levels of MK-2206 in combination with chemotherapy and targeted therapy agents in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT00848718
- Testing
- MK-2206, docetaxel, erlotinib
- Volunteers
- 77 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1)
Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
This is a research study in 2 parts assessing the following parameters of the combination of the study drug called bosutinib, and a drug called capecitabine: the safety, how well the subject's body handles the study drug, and…
- Conditions
- Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1), Advanced Colorectal Cancer (Part 1), Advanced Cholangiocarcinoma (Part 1)
- Trial name
- NCT00959946
- Testing
- Bosutinib, Capecitabine
- Where
- 7 sites in United States, Australia and 4 more
- Volunteers
- 32 people
- Sponsor
- Pfizer
Solid Tumor, Multiple Myeloma
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
This study will look for the highest tolerated dose of dalotuzumab (MK-0646) given as weekly, every other week. or a every three week infusion.
- Trial name
- NCT00701103
- Testing
- Dalotuzumab
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Pancreatic Cancer
High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
This is a multicenter, single arm, 3-cohort, open-label trial of high dose Vitamin C intravenous infusion in subjects with solid tumor malignancies who are eligible for resection (cohort A) or with extended RAS (e.g.KRAS or NRAS)…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT03146962
- Testing
- Vitamin C
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Weill Medical College of Cornell University
Solid Tumor, Adult, Triple Negative Breast Cancer
AVID100 in Advanced Epithelial Carcinomas
Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT03094169
- Testing
- AVID100 IV
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Formation Biologics
Cancer, Tumors
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.
- Conditions
- Cancer, Tumors, Neoplasm, Malignancy
- Trial name
- NCT03251924
- Testing
- BMS-986226, Nivolumab, Ipilimumab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
Neoplasm
Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
This clinical study evaluates the safety, tolerability, pharmacokinetics, and immunogenicity of dalotuzumab (MK-0646) in participants with relapsed or refractory locally advanced or metastatic solid tumors using once weekly and…
- Trial name
- NCT00694356
- Testing
- Dalotuzumab
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial
- Trial name
- NCT00828919
- Testing
- axitinib, crizotinib
- Where
- 34 sites in United States, Czechia and 9 more
- Volunteers
- 52 people
- Sponsor
- Pfizer
Advanced Solid Malignancies
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
This is a Phase I, open label, Dose Escalation study of oral administration of single agent MLN0128 in participants with Advanced Malignancies followed by an Expansion Phase in participants with renal cell carcinoma, endometrial…
- Trial name
- NCT01058707
- Testing
- MLN0128
- Where
- 16 sites in United States, Spain
- Volunteers
- 198 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cancer
VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
The purpose of this study is to determine how dosing with ketoconazole (Nizoral) or esomeprazole (Nexium) affects the pharmacokinetics of oral pazopanib.
- Trial name
- NCT01205230
- Testing
- pazopanib
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Neoplasms, Breast Cancer
A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02129205
- Testing
- PF-06650808
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- Pfizer
Solid Tumours
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
This is an open-label 2-part Phase I study in patients with advanced solid tumours. Part A of the study (mandatory) will assess the effect of olaparib on the pharmacokinetics (PK) of anastrozole, letrozole and tamoxifen and vice…
- Trial name
- NCT02093351
- Testing
- Olaparib, Tamoxifen, Anastrozole
- Where
- 14 sites in Belgium, Denmark and 3 more
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.